Merck & Co., Inc. vs PPG Industries, Inc. — how do they compare? Merck & Co., Inc. trades at $130.23 (market cap $323.00B), while PPG Industries, Inc. trades at $115.82 (market cap $25.67B). The key difference: Merck & Co., Inc. is far larger — about 12.6× PPG Industries, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.6%). Which is the better fit depends on your goals.
| MRK | PPG | |
|---|---|---|
Market Cap | $323.00B | $25.67B |
Sector | Health | Basic Materials |
52-Week High | $131.84 | $131.56 |
52-Week Low | $77.60 | $94.34 |
Enterprise Value | $369.77B | $31.54B |
Dividend Yield | 2.6% | 2.56% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
PPG Industries trades at $119.72, up 2.19% on the day, with a bullish technical outlook supported by moving averages. The company reported Q2 2026 sales growth of 7% year-over-year but missed EPS estimates. Recent dividend hikes and strong cash flow highlight financial health, while valuation ratios like a P/E of 17.18 suggest reasonable pricing. Analyst consensus is positive with a $129.17 price target.
Outlook remains favorable due to consistent dividend growth and operational strength, though risks include cost pressures and mixed earnings performance. The stock offers a balanced opportunity with upside potential from analyst targets, but investors should monitor margin trends and macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →